{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"US_8637258_B2","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"095-666-365-537-941"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":10790,"type":"PATENT","title":"Bristol University - Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":3272,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8258,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: \"bristol Univ*\";
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2425
Search Applicants and Owners separately: Univ* Genoa. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 136
Search Applicants and Owners separately: \"bristol Univ*\";
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 2425
Search Applicants and Owners separately: Univ* Genoa. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 136
(a) immunizing a non-human mammal with an immunogen comprising an immunogenic extracellular portion of a human KIR2DL polypeptide;\n
(b) preparing antibodies from said immunized mammal, wherein said antibodies bind said human KIR2DL polypeptide;\n
(c) selecting antibodies of (b) that cross-react with at least two different human KIR2DL polypeptides that each recognizes a different group of HLA-C class I allotypes; and\n
(d) selecting antibodies of (c) that potentiate NK cell activity."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, which further includes (e) selecting and isolating an antibody from the antibodies of (d) that binds a NK cell or KIR2DL polypeptide of a primate."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 1, wherein said antibody competes with the DF-200 antibody (deposited as CNCM I-3224) for binding to said KIR polypeptide."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the order of steps (c) and (d) is optionally reversed."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, further comprising the step of preparing a chimeric, or humanized antibody from the selected antibody which cross-reacts with at least two different human KIR2DL polypeptides that each recognizes a different group of HLA-C class I allotypes."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, further comprising the step of preparing an antibody fragment which cross-reacts with at least two different human KIR2DL polypeptides that each recognizes a different group of HLA-C class I allotypes."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 6, wherein the antibody fragment is a Fab, Fab′, Fab′-SH, F(ab′)2, Fv, diabody, single-chain antibody fragment, or a multi-specific antibody comprising a number of different antibody fragments."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the at least two different human KIR2DL polypeptides of step (c) comprise KIR2DL1, KIR2DL2, and/or KIR2DL3."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the antibody prepared in step (b) is a monoclonal antibody."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the antibodies selected in step (d) cause an at least about 50% potentiation in NK cytotoxicity, as measured by a chromium release test of cytotoxicity."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the antibody binds to substantially the same epitope as the DF-200 antibody (deposited as CNCM I-3224)."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the antibody selected in step (b) inhibits the binding of a HLA-c allele molecule having a Lys residue at position 80 to a human KIR2DL1 receptor, and the binding of a HLA-C allele molecule having an Asn residue at position 80 to human KIR2DL2/3 receptors."],"number":12,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the human KIR2DL polypeptide comprises at least one extracellular Ig domain of the KIR2DL receptor."],"number":13,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the human KIR2DL polypeptide comprises both extracellular IgG domains of the KIR2DL receptor."],"number":14,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}